Ocrevus rapidly depletes immune B-cells in people with MS, but ongoing treatment also leads to changes in immune T-cells, a study found.
The CD20 inhibitor Ocrevus (ocrelizumab) rapidly depletes immune B-cells in people with multiple sclerosis (MS), as expected, but ongoing treatment also leads to changes in immune T-cells, a new stud…
Artikel ini bersumber dari Multiple Sclerosis News Today pada September 9, 2025 at 6:27 PM.
To view and participate in discussions about this article, please visit the original source.
View Original Article